CU20150067A7 - 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis - Google Patents
3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosisInfo
- Publication number
- CU20150067A7 CU20150067A7 CUP2015000067A CU20150067A CU20150067A7 CU 20150067 A7 CU20150067 A7 CU 20150067A7 CU P2015000067 A CUP2015000067 A CU P2015000067A CU 20150067 A CU20150067 A CU 20150067A CU 20150067 A7 CU20150067 A7 CU 20150067A7
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- dimetilpropan
- ateroclerosis
- carboxi
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 abstract 1
- DQSCWIHGBKJVRY-UHFFFAOYSA-N 3-carboxypropyl-ethyl-dimethylazanium;dihydrogen phosphate Chemical compound OP(O)([O-])=O.CC[N+](C)(C)CCCC(O)=O DQSCWIHGBKJVRY-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describe un compuesto y se presenta su fórmula 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio y sus sales farmacéuticamente aceptables: fumarato de hidrógeno de 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio y fosfato de dihidrógeno 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio. El compuesto y las sales de la presente invención es efectivo para el tratamiento de la aterosclerosis por disminución del área y volumen total de las lesiones ateroesclerótica, con fórmula: ESPACIO PARA FÓRMULA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 | ||
| PCT/EP2013/077291 WO2014096133A1 (en) | 2012-12-20 | 2013-12-19 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20150067A7 true CU20150067A7 (es) | 2016-01-29 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000067A CU20150067A7 (es) | 2012-12-20 | 2015-06-19 | 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (es) |
| AR (1) | AR094084A1 (es) |
| BR (1) | BR112015014161B1 (es) |
| CA (1) | CA2895574C (es) |
| CU (1) | CU20150067A7 (es) |
| JO (1) | JO3117B1 (es) |
| MX (1) | MX362762B (es) |
| PE (1) | PE20151587A1 (es) |
| TN (1) | TN2015000236A1 (es) |
| WO (1) | WO2014096133A1 (es) |
| ZA (1) | ZA201505093B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| JP5706409B2 (ja) * | 2009-06-25 | 2015-04-22 | テトラ，エスイーアー | 新規なサリチル酸塩 |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| US20140088125A1 (en) * | 2011-04-27 | 2014-03-27 | Jsc Grindeks | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/ar active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/es unknown
- 2013-12-19 MX MX2015008138A patent/MX362762B/es active IP Right Grant
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/es not_active Application Discontinuation
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/pt active IP Right Grant
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/zh active Active
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en active Application Filing
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/fr unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/es unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104869988B (zh) | 2017-07-28 |
| MX2015008138A (es) | 2016-04-25 |
| CA2895574A1 (en) | 2014-06-26 |
| BR112015014161B1 (pt) | 2021-02-17 |
| AR094084A1 (es) | 2015-07-08 |
| JO3117B1 (ar) | 2017-09-20 |
| MX362762B (es) | 2019-02-06 |
| TN2015000236A1 (en) | 2016-10-03 |
| BR112015014161A2 (pt) | 2017-07-11 |
| CA2895574C (en) | 2019-11-26 |
| WO2014096133A1 (en) | 2014-06-26 |
| PE20151587A1 (es) | 2015-12-05 |
| CN104869988A (zh) | 2015-08-26 |
| ZA201505093B (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| DOP2014000064A (es) | Compuestos 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas | |
| ECSP16073171A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
| DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| CO7180199A2 (es) | Imidazotriazincarbonitrilos útiles como inhibidores de cinasa | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| CR20130023A (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
| UY33910A (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC | |
| CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
| BR112013025415A2 (pt) | métodos para aumentar eficácia de terapia de câncer de folr1 | |
| GT201400131A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| BR112015000399A2 (pt) | derivados de pirazolil pirimidina | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| CR20160352A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CR20140535A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| CR20150211A (es) | Compuestos diméricos | |
| CR20140553A (es) | Compuestos de fenoxietil piperidina | |
| CL2014002978A1 (es) | Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |